MedPath

Evaluation of Mechanical Thrombectomy in Acute Ischemic Stroke Related to a Distal Arterial Occlusion

Not Applicable
Recruiting
Conditions
Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
Interventions
Procedure: Mechanical Thrombectomy
Drug: Best medical treatment alone
Registration Number
NCT05030142
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Brief Summary

Mechanical thrombectomy (MT) has shown its effectiveness for the treatment of acute ischemic stroke (AIS) related to large vessel occlusion and rapidly became a cornerstone in the management of these patients. No strong evidence is available on the benefit of MT in AIS related to more distal occlusions. Some previous observational studies suggested a possible benefit but most of them were single-centre and retrospective studies providing a very low level of evidence. To date, no randomized controlled trial has been conducted in this indication, which represents 10% to 20% of all AIS involving intracranial vessel occlusions.

This research is a multicenter open randomized controlled trial with two parallel groups : best medical treatment alone VS mechanical trombectomy + best medical treatment.

Detailed Description

The main objective of this trial is to assess the efficacy of mechanical thrombectomy in addition to the best medical treatment as compared to the best medical treatment alone in AIS related to a distal intracranial artery occlusion. The medical device used will be a stent retriever among : Trevor NXT ProVue Retriever ; Catchview mini ; pReset Lite ; Tigertriever13, and the medical treatment used will depend on the stroke's etiology and will consist of IV trhombolysis or tenecteplase or antiplatelet therapy or anticoagulant therapy ... The main inclusion criteria are : 1) patients aged ≥ 18 years ; 2) Delay between symptoms onset and expected groin puncture ≤ 6h ; 3) Symptomatic occlusion as evaluated by a National Institute of Health Stroke Score (NIHSS) ≥ 5 ; 4) Distal occlusion evaluated on CT angiography (CTA) or magnetic resonance imaging (MRI) and defined as an occlusion in one of the following segments : a-Distal M2, above the mid-height of the insula, b-M3 segment, c-Posterior cerebral artery (PCA) = P1, P2 or P3 segment, d-Anterior cerebral artery (ACA) : A1, A2 or A3 segment ; 5) Written informed consent signed by the patient or the trustworthy person / family member / close relative, or inclusion in case of emergency and written informed consent will be signed by the patient (if needed by trustworthy person, family member or close relative) as soon as possible (article L1122-1-2 of the French Public Health Code).

The secondary objectives and endpoints are to evaluate the : 1) Success of the procedure defined as recanalization of the occluded vessel, evaluated on the AOL (Arterial Occlusion Lesion) score within 48 hours ; 2) Excellent clinical outcome (defined as a modified Rankin scale \[mRS\]≤1) at 3 months ; 3) Safety with reporting of all adverse and serious adverse events with a particular attention to perforation rate, embolus migration in a new territory and symptomatic hemorrhagic complications ; 4) Death rate up to 3 months ; 5) Cost effectiveness and utility of the procedure. The study will also evaluate the rate of angiographic reperfusion in the intervention group on the final angiogram at the end of the MT (which is part of the intervention) using the modified thrombolysis in cerebral infarction (mTICI) (2B-3) and the eTICI.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
488
Inclusion Criteria
  • Patients aged ≥ 18 years

  • Delay between symptoms onset and expected groin puncture ≤ 6 h

  • Symptomatic occlusion as evaluated by a National Institute of Health Stroke Score (NIHSS) ≥ 5

  • Distal occlusion evaluated on CT angiography (CTA) or magnetic resonance imaging (MRI) and defined as an occlusion in one of the following segments:

    • Distal M2, above the mid-height of the insula
    • M3 segment
    • Posterior cerebral artery (PCA): P1, P2, P3 segments
    • Anterior cerebral artery (ACA): A1, A2, A3 segments
  • Written informed consent signed by the patient or the trustworthy person / family member / close relative, or inclusion in case of emergency and written informed consent will be signed by the patient (if needed by trustworthy person, family member or close relative) as soon as possible (article L1122-1-2 of the French Public Health Code)

Exclusion Criteria
  • Pregnancy or breastfeeding woman
  • Contra-indication for femoral, radial or humeral arterial puncture
  • Tandem occlusion (i.e.: concomitant cervical and intra-cranial arterial occlusion)
  • Allergy to iodinated contrast media
  • Known renal insufficiency (confirmed by previous result of creatinine clearance < 30 ml/min)
  • Secondary distal occlusion (i.e., complicating a MT for a proximal occlusion, or any other endovascular intracranial procedure)
  • Aortic dissection
  • Asymptomatic or minor stroke (i.e.: NIHSS < 5)
  • Pretreatment mRS > 1 (pre-stroke)
  • Anticipated limitations for anesthesia
  • Participation in another trial (Jardé 1 and Jardé 2)
  • Absence of affiliation to National French social security system
  • Under legal protection measure (tutorship or curatorship) and patient deprived of freedom
  • A pre-existing hemorrhage in the brain tissue fed by the target vessel
  • Known hypersensitivity to nickel/titanium
  • Stenosis and/or with a stent proximal to the site of the thrombus which could preclude the retrieval of the stent retriever
  • Angiographic evidence of carotid dissection

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Mechanical thrombectomyMechanical ThrombectomyMechanical thrombectomy (using a stent retriever among the following:Trevo NXT ProVue Retriever, Catchview mini, pReset Lite, Tigertriever 13) in association with the best medical treatment (usual care)
Active ComparatorBest medical treatment aloneBest medical treatment alone (usual care)
Primary Outcome Measures
NameTimeMethod
Good clinical outcome (defined as a modified Rankin Scale [mRS] ≤ 2)At 3 months

mRS of 0-2 (evaluated by an independent assessor blinded to the intervention received by the patient)

Secondary Outcome Measures
NameTimeMethod
Safety : incidence of adverse eventsAt 3 months

Reporting of all adverse events

Death rateAt 3 months

Mortality

Angiographic reperfusion in the intervention groupEnd of the mechanical thrombectomy procedure

Use of the mTICI score (successful reperfusion: mTICI 2b-3) and the eTICI (extended thrombolysis in cerebral infarction) score (successful reperfusion: eTICI ≥ 2b67) on the control digital subtraction angiography (DSA)

Perforation rateEnd of mechanical thrombectomy procedure

Defined as contrast material extravasation either on digital subtraction angiography \[DSA\] or control CT scan

Embolus migration in a new territoryEnd of mechanical thrombectomy procedure

evaluated on digital subtraction angiography \[DSA\]

Symptomatic intracranial hemorrhagewithin 7 days

evaluated on CT-scan or MRI according to the ECASS II criteria

Recanalization of the occluded vessel48 hours after the mechanical thrombectomy

Evaluation of AOL (Arterial Occlusion Lesion scale) ≥ 2 on vascular brain imaging (magnetic resonance MR) or computed tomography (CT) angiography in patients belonging to both arms

Excellent Clinical outcome (defined as a modified Rankin Scale [mRS] ≤ 1)At 3 months

mRS of 0-1 (evaluated by an independent assessor blinded to the intervention received by the patient)

Subarachnoid hemorrhagewithin 48 hours

evaluated on CT-scan or MRI and define as the abnormal presence of blood within the subarachnoid space presence of blood within the subarachnoid space

Safety : incidence of serious adverse eventsAt 3 months

Reporting of all serious adverse events

Utility of the procedureAt 3 months

Incremental cost utility ratio

Cost effectivenessAt 3 months

Cost per additional survivor (health-economics analysis)

Trial Locations

Locations (1)

Frédéric CLARENCON

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath